NCT07209189View on ClinicalTrials.gov

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

October 1, 2030

Study Completion Date

December 1, 2030

Conditions
Head and Neck CancerSquamous Cell CarcinomaOral Cavity CancerOropharyngeal CancerLaryngeal CancerSinonasal Squamous Cell CarcinomaHPV (Human Papillomavirus)-Associated CarcinomaSkull Base TumorsHPV 16 Positive Oropharyngeal Tumors (OPC)
Interventions
DRUG

Toripalimab + Chemotherapy

"Toripalimab is the study drug and will be given via IV in all arms except Rad+/-Chem : Adjuvant radiation or chemoradiotherapy"

DRUG

Toripalimab

Study drug

RADIATION

Chemoradiotherapy or radiation

In the adjuvant phase, either radiation or chemoradiotherapy is used for treatment

Sponsors

Collaborators (1)

Coherus Oncology, Inc.
All Listed Sponsors
collaborator

Coherus Oncology, Inc.

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT07209189 - Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN) | Biotech Hunter | Biotech Hunter